IDH1 Mutation Clinical Trials in Boston, Massachusetts
3 recruitingBoston, Massachusetts
Showing 1–3 of 3 trials
Recruiting
Phase 2
Ivosidenib as Post-HSCT Maintenance for AML
Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Phase 3
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC136 enrolled114 locationsNCT06127407
Recruiting
Phase 2
Study of Olutasidenib and Temozolomide in HGG
Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974